
Monaco F1 GP Date Stepping Out of Indy 500's Shadow Just Might Save It
The latest car news, reviews, and features.
Around this time each year, the racing world is inundated with a flurry of headlines, social media threads, and think pieces slamming Formula 1's Crown Jewel, the Monaco Grand Prix. The main thing they all have in common is the word 'boring.' This Sunday was no different, despite F1's best and latest efforts.
Since F1 first broke ground in the U.S., it has been tasked with competing with its closest cousin, IndyCar—and its own pride and joy, the Indy 500. When the two occupy the same Sunday, followed by NASCAR's Coca-Cola 600, it is nearly impossible not to compare F1's most glamorous race with 'The Greatest Spectacle in Racing.' As the sport fails to find solid ground in the principality and the GP's title is up for contention with calls to strike it altogether from the 24-race calendar, moving the Grand Prix date to the first weekend in June starting next year could be the best thing for its future viability.
Sunday, the day that some racing fanatics wait all year to enjoy, started on the narrow, winding streets of Monte-Carlo. F1 introduced a mandatory two-pitstop rule this year in an effort to slice through fan complaints that the highly anticipated annual race looked more like a slow Sunday drive than a wheel-to-wheel fight to the finish line. Monaco's greatest challenge as the sport, its formula, and its cars evolved through the decades, is overtaking—or a lack thereof. In 2023, F1 drivers overtook the car in front just 22 times, which was nearly double the year before. In 2024, that number was just four. Getty
While F1's new race format gave viewers more race substance to sink their teeth into and looked less like a funeral procession compared to previous years, it didn't shake up the grid as much as promised. Lando Norris, who started on pole, finished the race first, followed by the same top four qualifying format: Charles Leclerc, Oscar Piastri, and Max Verstappen. While a select few drivers took full advantage of the new regulations—like Oliver Bearman starting dead last and clawing his way just outside the points to P12—most remained within one or two places from where they started.
After the checkered flag flew and trackside viewers returned to their yacht parties, drivers were critical of the new format. Carlos Sainz said it slowed down an already snail-like 78 laps and created contrived racing: 'In the past, there were huge penalties for manipulating a race. Ultimately, we are not crashing, but we are driving so slow that we are manipulating a race.' Sainz and fellow Williams driver Alex Albon took turns holding up the two Mercedes so both could pit without losing points-scoring position. Verstappen had a similar outlook. 'You can't race here. It doesn't matter what you do. One stop, 10 stops,' the Red Bull driver said while joking that Mario Kart-like obstacles would improve the race.
Over 4,500 miles away, the 109th running of the Indianapolis 500 supplied the kind of racing F1 desperately lacked. The Indy 500 can be summed up in one statistic: It is the largest annual single-day non-religious gathering of human beings on earth. (Although, for a city with a bit of a one-track mind, the 'non-religious' part might be up for debate.) And while Monaco carries a similar fidelity for motor racing, the two race-host locations speak to opposite viewership experiences. One is the glitz and glamour synonymous with F1's multi-million dollar drivers and the tax-free seaside pocket of paradise they inhabit. The other is more modest and is flavored with something fundamentally Americana. Both are desperately trying to catch more Americans' eyes, however. Getty
IndyCar has attempted to recreate F1's American success, whether through its own docuseries or relying on content creators and influencers to remain relevant at the top of fans' social media feeds—all while insisting it cannot be compared to its European counterpart. Whether it is F1's star-studded cast of drivers, yacht-dotted trackside charm, or globe-trotting tour around the world, the series has created a cult-like following in the U.S. that IndyCar just hasn't seemed to land. Despite IndyCar's tendency to outperform F1 in U.S. TV viewership—racking in an average of 1.7 million viewers per race on NBC in 2024 compared to F1's 1.11 average ESPN spectators—F1's appeal has swelled rapidly, with a 2022 poll reporting that 28 percent of American adults considered themselves F1 fans. In 2024, it became the most popular yearly sporting series with 750 million global fans, according to Nielsen Sports.
But despite the series' commercial success in the States over the past six years after Netflix's sporty and soapy peek inside the lives of F1's 20 drivers was released, the European racing series hasn't brought much of a fight to the day it matters most. For all that Formula Fever has achieved, F1 has failed to replicate an event like the Indy 500.
Once the 'Crown Jewel' of the F1 calendar, the Monaco GP's record U.S. TV viewership in 2024—coming in at 1.965 million people tuning into ESPN —failed to come anywhere close to the series' string of new stateside grands prix. The Miami GP plucked the crown from Monaco with 3.1 million ABC viewers in 2024, a new record for the sport's U.S. TV audience.
A new day on the calendar won't change the Monaco GP's fundamental flaws, but it could lessen expectations by not sharing IndyCar's biggest day of the year.
Got a tip? Email us at tips@thedrive.com
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Cory Booker Is Turning His Record-Setting Senate Speech Into a Book
If you purchase an independently reviewed product or service through a link on our website, Rolling Stone may receive an affiliate commission. Cory Booker is turning his record-setting Senate speech into a book. The New Jersey senator, who spoke for just over 25 hours on March 31 into April 1, railed against the Trump administration's threats to Social Security, Medicare, and Trump's attacks on the judiciary in a speech that set a record for the longest Senate floor speech in history. More from Rolling Stone F1 Star Charles Leclerc's New Headphones Collab Sold Out In Minutes - Here's How to Get An Almost Identical Pair Adults Are Using These Coloring Books to Help Reduce Anxiety - Here's Where to Buy Them Online for Under $7 Indiana Fever vs. Washington Mystics Livestream: How to Watch the WNBA Game Online The book, titled Stand, was announced on May 28 by The St. Martin's Publishing Group. It will be published on Nov. 11, 2025, and is available for preorder now. According to the publisher's notes, the book 'expands on' Booker's speech and 'offers a compelling vision for the future to readers who are eager to make a difference.' $30.99 Buy Now On Amazon Buy Now at barnes&noble Notably, Booker's speech surpassed a record previously set by Strom Thurmond, who filibustered the Civil Rights Act of 1957 for just over 24 hours. However, Booker's speech was not a filibuster because it was not intended to stop a specific piece of legislation. Instead, Booker spoke broadly against the Trump administration's policies. Booker addressed the decision not to target a specific bill in an interview with Rolling Stone in May. 'In the modern Senate, it's very hard to even get control of the floor. I said to my team, 'How did Ted Cruz get control of the floor? How did Rand Paul? Figure out how they got control.' The person in the cloakroom told me, very annoyingly, 'We let [Rand Paul take the floor] because he promised it was only going to be a couple minutes — and he lied through his teeth.… Are you willing to lie to [Senate Majority Leader John] Thune?' I said, 'That's not the way I roll. I'm not going to lie, so let's just let them know that I'm going to take control of the floor and hold it for as long as I possibly can.'' Best of Rolling Stone The Best Audiophile Turntables for Your Home Audio System


Fox Sports
2 hours ago
- Fox Sports
Race Names Unveiled for Sukup INDYCAR Race Weekend at Iowa
INDYCAR Celebrating speed, precision and innovation – hallmarks in racing and modern agriculture – Sukup Manufacturing Co. and INDYCAR announced May 28 the race names for the two NTT INDYCAR SERIES 275-lap races during the upcoming Sukup INDYCAR Race Weekend, July 11-13 at Iowa Speedway. The Saturday, July 12 race in Iowa will be the Synk 275 (5 p.m. ET, FOX, FOX Sports app, INDYCAR Radio Network) while the race Sunday, July 13 will be the Farm to Finish 275 (1 p.m. ET, FOX, FOX Sports App, INDYCAR Radio Network) at the 'Fastest Short Track on the Planet.' As a family-owned leader in grain storage and handling solutions, Sukup – title sponsor of Sukup INDYCAR Race Weekend – will bring its legacy of innovation to its home track as the Sheffield, Iowa-based company will highlight American farmers and the cutting-edge technologies that support the farming industry during the event. Saturday's NTT INDYCAR SERIES race will focus on Sukup's latest advancements in grain management systems. Honoring Sukup's revolutionary Synk product line, which unifies grain monitoring and measurement systems into one streamlined, easy-to-use platform, the Synk 275 will serve as the 11th round of the 17-race NTT INDYCAR SERIES season. Focused on celebrating and supporting America's grain farmers, Sunday's Farm to Finish 275 will close out what promises to be an action-packed weekend at the unique, .894-mile oval in Newton, Iowa. Iowa Speedway's doubleheader weekend – the only on the 2025 NTT INDYCAR SERIES schedule – is set to deliver even more high-speed drama in 2025. Both NTT INDYCAR SERIES races will be extended to 275 laps, 25 more than last year's twin 250-lap contests. This change increases each race distance from approximately 218 to 240 miles and is part of a broader initiative by INDYCAR and FOX Sports to enhance the fan experience by lengthening six of the 17 races on this year's NTT INDYCAR SERIES schedule. The goal is to amplify the intensity, the strategy and the spectacle that define INDYCAR racing. recommended

Wall Street Journal
3 hours ago
- Wall Street Journal
How Ozempic's Maker Lost Its Grip on the Obesity Market It Created
In 2023, Novo Nordisk NVO -2.61%decrease; red down pointing triangle was the most valuable company in Europe, surpassing LVMH on the back of soaring demand for Ozempic and Wegovy. Today, the Danish company has lost its grip on the anti-obesity market it carved out. The company has lost market share amid production missteps and a bungled rollout of Wegovy that led to shortages. Its U.S. rival Eli Lilly LLY -0.80%decrease; red down pointing triangle—initially in the rearview mirror—has been proven to have the more effective weight-loss drug and a more promising pipeline of next-generation treatments. Novo Nordisk's research-and-development machine has disappointed, and a key marketing strategy was slow to get off the ground. Novo Nordisk's ability to stay atop a market that analysts see growing to $150 billion in annual sales is now in doubt. Its controlling shareholder this month forced a surprise ouster of the company's chief executive, Lars Fruergaard Jørgensen. And while it is still generating multibillion-dollar sales for Ozempic and Wegovy, shares have tumbled more than 50% over the past year. If Novo Nordisk doesn't turn things around, it could join a long list of companies that blew a first-mover advantage, from Sunshine Biscuits—whose Hydrox cookies were overtaken by now-iconic Oreos—to the Myspace social network. 'Everyone wants to be the first footprints on the empty beach,' said Americus Reed, marketing professor at the Wharton School of the University of Pennsylvania. 'But it depends on how you land on that first move. The second mover is watching them make mistakes. You're able to identify those and not make those mistakes.' A Novo Nordisk spokeswoman said the company remains the global-volume market leader in GLP-1 drugs, serving nearly two-thirds of patients taking them for diabetes and obesity. Some investors and industry watchers say Novo Nordisk's troubles stem from a cautious, reactive approach starting when the market first burst onto the scene, in contrast with a faster, more aggressive tack in production and marketing by Lilly. 'Novo is always a step behind,' said Yuri Khodjamirian, chief investment officer at Tema ETFs, which owns Novo Nordisk shares. One of Novo Nordisk's early stumbles was underestimating the demand for Wegovy—the weight-loss version of semaglutide, the same compound as diabetes drug Ozempic—ahead of its 2021 launch. The company's planning was informed by its experience generating modest sales for an earlier weight-loss drug, Saxenda. Doctors were skeptical of it, and many health-insurance plans in the U.S. didn't cover weight-loss drugs. Novo Nordisk thought Wegovy might run into the same market constraints as Saxenda, so the company planned modest production levels, using a combination of in-house and contract manufacturing capacity. It wasn't enough. It took only five weeks for the prescription rate of Wegovy to exceed the level that Saxenda had taken five years to reach. Jørgensen recalled later, in an interview in 2024, that he initially thought: ''That's patients who've been lined up, there's pent-up demand, it will normalize.' It didn't. It just kept growing.' The company responded by limiting demand—the last thing a drugmaker wants to do with a new product. Sales representatives asked doctors not to start new patients. The company resorted to rationing by withholding the lower, starter doses for new patients, to conserve supplies for existing patients taking the higher doses. The shortages opened the door for competition. They made it legal for special pharmacies in the U.S. to make compounded, copycat versions of semaglutide that sold for much less than list prices for Ozempic and Wegovy. Telehealth firms capitalized on the new, lower-cost supply by hawking the compounded versions, taking away market share from Novo Nordisk. The shortages gave rival Eli Lilly time to catch up. Lilly introduced Mounjaro for diabetes in 2022, followed by Zepbound, a weight-loss version of the same drug, in 2023. Zepbound has been shown in studies to induce greater weight loss than Wegovy, more than 20% of body weight. Although Lilly also encountered shortages due to high demand, it was able to resolve them more quickly than Novo Nordisk. Now, weekly U.S. prescriptions for Lilly's Zepbound have surpassed Wegovy's. Mounjaro still trails Ozempic but is closing the gap. Novo Nordisk has spent billions of dollars trying to expand manufacturing capacity, including an unusual deal last year for its controlling foundation to acquire the contract manufacturer Catalent for $16 billion. The R&D race for future weight-loss drugs also has tilted in Eli Lilly's direction. Lilly has reported favorable clinical-trial data for two closely watched experimental drugs, including a pill version that analysts think could be appealing to people who don't want injections. Novo Nordisk, meanwhile, has had some R&D disappointments, including studies of an experimental combination weight-loss drug dubbed CagriSema. The less-than-expected results of one study sent Novo Nordisk shares plunging more than 20% in one day in December, wiping out nearly $100 billion in stock-market capitalization for the company. Some analysts have cut their sales forecasts for the drug. Lilly has gained an edge on the marketing front as well. The company beat Novo Nordisk to the punch in launching a direct-to-consumer, online service selling weight-loss drugs at discounted cash prices, aimed at people who don't have insurance coverage. And it was first to strike a deal with a big telehealth firm, Ro, to sell a discounted weight-loss drug. Novo Nordisk eventually made similar moves, but months after Lilly. 'They seem to be missing a lot of these kinds of strategic endeavors to help sell into a market that is different from a lot of pharma markets,' said BMO Capital Markets analyst Evan David Seigerman. The Novo Nordisk spokeswoman said the company resolved its shortages before announcing its direct-to-patient service and striking telehealth deals. Novo Nordisk isn't out of the race. The company can still turn things around by leaning into CagriSema, which generated solid weight-loss data even if it missed expectations, and by developing other new drugs that target various segments of the growing market, Seigerman said. More recently, Novo Nordisk has shown signs of being more aggressive. It signed a deal with CVS to make Wegovy the preferred weight-loss drug for members of its drug-benefit plans. Author Hanne Sindbæk, who has written two books about Novo Nordisk, says there has been an eternal tug of war inside the company between those who are guided by values—the idea that the company works for the common good rather than simply to make a profit—and those who run the business. If Novo Nordisk wants to stay in the game, it may have to lean toward the latter in choosing its next CEO. Jørgensen, the outgoing CEO, is still in his role while the company searches for a new chief. His predecessor as CEO, Lars Rebien Sørensen, who is chairman of the foundation that has voting control of the drugmaker's shares, will join the Novo Nordisk board of directors. 'Now they need somebody more business-driven,' Sindbæk said. Write to Peter Loftus at and Noemie Bisserbe at